GenSight Biologics S.A., a clinical‑stage gene therapy company focused on retinal neurodegenerative diseases and central nervous system disorders, announced the results of its Extraordinary General Meeting held on January 28, 2026. Shareholders approved all resolutions presented, except for Resolution 8 concerning a reserved capital increase, which was rejected. The company said the outcome does not affect its ability to undertake capital transactions or pursue strategic financing options.
Among the approvals, shareholders renewed all financial authorisations, replacing those previously used, which the company said provides necessary financial flexibility to pursue its strategic objectives, including ongoing development of its gene therapy pipeline. The meeting was chaired by Jan Eryk Umiastowski, Deputy CEO and Chief Financial Officer, who also addressed a written shareholder question and provided clarifications on other matters during the session.
GenSight Biologics’ pipeline includes candidates such as GS010 (lenadogene nolparvovec), in Phase III development for Leber hereditary optic neuropathy (LHON), a rare mitochondrial disease that leads to irreversible vision loss. The company’s gene therapy programmes leverage technologies including mitochondrial targeting sequences and optogenetics to potentially preserve or restore visual function in patients with retinal degeneration.
Information on individual vote tallies and a replay of the meeting are available on the company’s investor relations website, and the company said it will continue to engage with shareholders as it advances its development and regulatory initiatives.
